| Gold shunt shines in study of patients with POAG
| Device leaves no filtering bleb, reduces IOP by 33%, has low rate of complications, physician says
| | Ophthalmology Times | Implantation of a glaucoma drainage device made entirely from medical-grade gold (SOLX GMS Plus Gold Shunt, SOLX Inc.) is a viable surgical option for primary open-angle glaucoma (POAG). |
| | Study results validate clinical trends showing increasing preference for tube surgery
| Complications associated with trabeculectomy have prompted search for better alternatives
| | Ophthalmology Times | | Complications associated with trabeculectomy have prompted a search for better alternatives. Practice pattern data from recent years show growing usage of tube implants. Results of the multicenter, randomized Tube vs. Trabeculectomy study offer validation for this trend. |
| | Study results highlight benefits of dorzolamide-timolol
| Second-line, fixed-combination therapy is safe and effective option to lower IOP
| | Ophthalmology Times | | Use of fixed-combination dorzolamide 2.0% and timolol 0.5% (dorzolamide-timolol; Cosopt, Merck) as a replacement or add-on is a safe and effective option to achieve further IOP lowering in patients. |
| | New preservative does not alter efficacy of travoprost
| Agent is intended to be less irritating to ocular surface, may keep eye healthier prior to surgery
| | Ophthalmology Times | | A new formulation of travoprost (Travatan Z, Alcon Laboratories) containing an ionic-buffered preservative (sofZia), and the older formulation (Travatan), preserved with benzalkonium chloride (BAK), had similar IOP-lowering effects in a group of patients who began treatment with the original drop then switched to the newer drug. The ionic-buffered agent is intended to be less toxic to the ocular surface than BAK, which could be significant in long-term glaucoma therapy. |
| |
| Important eye health issues examined in Ophthalmology journal
| | Ophthalmology Times | Three studies on eye health examine the role of antioxidant supplements, the relationship of visual acuity and mortality, and the causes of glaucoma in the May 2008 issue of Ophthalmology, the journal of the American Academy of Ophthalmology.
|
| | Risk of glaucoma increases with diabetes, study supports
| | Ophthalmology Times | | It appears that diabetic retinopathy is not the only eye disease associated with diabetes, according to a study, which found that women with diabetes have about a 70% increased risk of developing the most common form of glaucoma—primary-open angle glaucoma—compared with women without diabetes. |
| | Alcon's Cary Rayment honored as a 'catalyst' for glaucoma work
| Commitment to glaucoma research strong after 25 years in eye-care industry
| | Ophthalmology Times | | Cary Rayment, who was honored Jan. 23 by the Glaucoma Research Foundation (GRF) with the 2008 GRF Catalyst Award, is leading his company's strategic plan to spend more than $3.5 billion on research over the next 5 years. |
|
| 
